<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01465191</url>
  </required_header>
  <id_info>
    <org_study_id>AAAI2804</org_study_id>
    <nct_id>NCT01465191</nct_id>
  </id_info>
  <brief_title>Effect of Mu-opioid Receptor Genetics on 3 Doses of Spinal Morphine for Postoperative Analgesia After Cesarean Section</brief_title>
  <official_title>Effect of OPRM1 Genotype on the Dose Response to Spinal Morphine for Post-Cesarean Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HYPOTHESIS: The response to a given dose of morphine given via a spinal anesthetic for&#xD;
      cesarean section will be affected by the genetics of the woman's mu-opioid receptor&#xD;
&#xD;
      Most women undergoing elective cesarean section (CS) receive spinal anesthesia, and most&#xD;
      receive a dose of preservative free morphine with the spinal anesthetic.&#xD;
      Spinally-administered morphine provides 16-24 hours of high quality pain relief. The dose&#xD;
      administered is usually 75-200 micrograms, but surprisingly few dose-response studies exist.&#xD;
&#xD;
      The mu-opioid receptor (OPRM1 gene)is the site of action of endogenous opioid peptides and&#xD;
      opioid analgesic drugs like morphine. There is a common genetic variant of this receptor at&#xD;
      the 40th amino acid of the protein, with asparagine and asparate being present in different&#xD;
      people. The less common variant (aspartate), present in 25-30% of the overall American&#xD;
      population (higher in Asian populations, lower in Blacks) at codon 40 that has been shown in&#xD;
      many studies to affect opioid analgesia.&#xD;
&#xD;
      This will be a randomized, blinded study of 3 doses of spinal morphine (50, 100, 150&#xD;
      micrograms) given to women undergoing elective cesarean section at term pregnancy. 300 women&#xD;
      will be studied (100 per dose). Blood will be obtained for genotyping of OPRM1 and other&#xD;
      genes that may affect pain and analgesic responses. The primary outcome will be the amount of&#xD;
      intravenous morphine patients self-administer in the 24 hours postsurgery.&#xD;
&#xD;
      The primary outcome (use of intravenous morphine) will be analyzed by dose, and within each&#xD;
      dose group by genotype of OPRM1. Secondary outcomes will include pain scores every 6 hours,&#xD;
      satisfaction with analgesia, side effects (itching, nausea/vomiting) by dose and genotype.&#xD;
&#xD;
      It is anticipated that there will be an interim data analysis at 150 evaluable subjects for&#xD;
      assessment of the dose response to morphine in the overall population; then a final analysis&#xD;
      at 300 subjects for the genetic effect assessment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Milligrams of Intravenous Morphine Used by Participant in First 24 Hours Postoperatively</measure>
    <time_frame>24 hours</time_frame>
    <description>IV morphine use in milligrams, by participant-controlled analgesia will be assessed every 6 hours for 24 hours postoperatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Pain at 6 Hours</measure>
    <time_frame>6 hours post-operatively</time_frame>
    <description>Visual analog pain scale measures pain on a 100 millimeter (mm) scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst pain imaginable&quot; (100mm). Pain measured at rest and with movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Pain at 12 Hours</measure>
    <time_frame>12 hours post-operatively</time_frame>
    <description>Visual analog pain scale measures pain on a 100 millimeter (mm) scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst pain imaginable&quot; (100mm). Pain measured at rest and with movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Pain at 18 Hours</measure>
    <time_frame>18 hours post-operatively</time_frame>
    <description>Visual analog pain scale measures pain on a 100 millimeter (mm) scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst pain imaginable&quot; (100mm). Pain measured at rest and with movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Pain at 24 Hours</measure>
    <time_frame>24 hours post-operatively</time_frame>
    <description>Visual analog pain scale measures pain on a 100 millimeter (mm) scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst pain imaginable&quot; (100mm). Pain measured at rest and with movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale- Nausea/Vomiting at 6 Hours</measure>
    <time_frame>6 hours post-operatively</time_frame>
    <description>Visual analog nausea/vomiting scale measures nausea and vomiting on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Nausea/Vomiting Imaginable&quot; (100mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale- Nausea/Vomiting at 12 Hours</measure>
    <time_frame>12 hours post-operatively</time_frame>
    <description>Visual analog nausea/vomiting scale measures nausea and vomiting on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Nausea/Vomiting Imaginable&quot; (100mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale- Nausea/Vomiting at 18 Hours</measure>
    <time_frame>18 hours post-operatively</time_frame>
    <description>Visual analog nausea/vomiting scale measures nausea and vomiting on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Nausea/Vomiting Imaginable&quot; (100mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale- Nausea/Vomiting at 24 Hours</measure>
    <time_frame>24 hours post-operatively</time_frame>
    <description>Visual analog nausea/vomiting scale measures nausea and vomiting on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Nausea/Vomiting Imaginable&quot; (100mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale Pruritus (Itching) at 6 Hours</measure>
    <time_frame>6 hours post-operatively</time_frame>
    <description>Visual analog pruritus scale measures itching on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Itching Imaginable&quot; (100mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale Pruritus (Itching) at 12 Hours</measure>
    <time_frame>12 hours post-operatively</time_frame>
    <description>Visual analog pruritus scale measures itching on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Itching Imaginable&quot; (100mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale Pruritus (Itching) at 18 Hours</measure>
    <time_frame>18 hours post-operatively</time_frame>
    <description>Visual analog pruritus scale measures itching on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Itching Imaginable&quot; (100mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale Pruritus (Itching) at 24 Hours</measure>
    <time_frame>24 hours post-operatively</time_frame>
    <description>Visual analog pruritus scale measures itching on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Itching Imaginable&quot; (100mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Patient Satisfaction With Analgesia at 24 Hours</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Visual analog patient satisfaction scale measures satisfaction with analgesia on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;Completely Dissatisfied&quot; (0mm) and the other labeled &quot;Completely Satisfied&quot; (100mm).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>50 micrograms (mcg) spinal morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 micrograms spinal morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 micrograms spinal morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section</description>
    <arm_group_label>100 micrograms spinal morphine</arm_group_label>
    <arm_group_label>150 micrograms spinal morphine</arm_group_label>
    <arm_group_label>50 micrograms (mcg) spinal morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy women undergoing elective cesarean&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  cardiovascular disease&#xD;
&#xD;
          -  analgesic medications&#xD;
&#xD;
          -  complications of pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard M Smiley, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Washington University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2011</study_first_submitted>
  <study_first_submitted_qc>November 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2011</study_first_posted>
  <results_first_submitted>October 26, 2020</results_first_submitted>
  <results_first_submitted_qc>November 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 10, 2020</results_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Richard M. Smiley</investigator_full_name>
    <investigator_title>Professr of Clinical Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>cesarean</keyword>
  <keyword>postoperative</keyword>
  <keyword>morphine</keyword>
  <keyword>genetics</keyword>
  <keyword>opioid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>50 Micrograms Spinal Morphine</title>
          <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
        </group>
        <group group_id="P2">
          <title>100 mcg Spinal Morphine</title>
          <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
        </group>
        <group group_id="P3">
          <title>150 mcg Spinal Morphine</title>
          <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>50 Micrograms Spinal Morphine</title>
          <description>these subjects will receive 50 mcg spinal morphine</description>
        </group>
        <group group_id="B2">
          <title>100 Micrograms Spinal Morphine</title>
          <description>these subjects will receive 100 mcg spinal morphine</description>
        </group>
        <group group_id="B3">
          <title>150 Micrograms Spinal Morphine</title>
          <description>these subjects will receive 150 mcg spinal morphine</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="6"/>
                    <measurement group_id="B2" value="33" spread="5"/>
                    <measurement group_id="B3" value="33" spread="6"/>
                    <measurement group_id="B4" value="33" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Milligrams of Intravenous Morphine Used by Participant in First 24 Hours Postoperatively</title>
        <description>IV morphine use in milligrams, by participant-controlled analgesia will be assessed every 6 hours for 24 hours postoperatively.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section</description>
          </group>
          <group group_id="O2">
            <title>100 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section</description>
          </group>
          <group group_id="O3">
            <title>150 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section</description>
          </group>
        </group_list>
        <measure>
          <title>Milligrams of Intravenous Morphine Used by Participant in First 24 Hours Postoperatively</title>
          <description>IV morphine use in milligrams, by participant-controlled analgesia will be assessed every 6 hours for 24 hours postoperatively.</description>
          <units>Milligrams</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="8" upper_limit="29"/>
                    <measurement group_id="O2" value="14" lower_limit="6" upper_limit="27"/>
                    <measurement group_id="O3" value="15" lower_limit="5" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS) Pain at 6 Hours</title>
        <description>Visual analog pain scale measures pain on a 100 millimeter (mm) scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst pain imaginable&quot; (100mm). Pain measured at rest and with movement.</description>
        <time_frame>6 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O2">
            <title>100 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O3">
            <title>150 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS) Pain at 6 Hours</title>
          <description>Visual analog pain scale measures pain on a 100 millimeter (mm) scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst pain imaginable&quot; (100mm). Pain measured at rest and with movement.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="10" upper_limit="39"/>
                    <measurement group_id="O2" value="25" lower_limit="8" upper_limit="43"/>
                    <measurement group_id="O3" value="15" lower_limit="2" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Movement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="27" upper_limit="62"/>
                    <measurement group_id="O2" value="43" lower_limit="28" upper_limit="65"/>
                    <measurement group_id="O3" value="30" lower_limit="13" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS) Pain at 12 Hours</title>
        <description>Visual analog pain scale measures pain on a 100 millimeter (mm) scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst pain imaginable&quot; (100mm). Pain measured at rest and with movement.</description>
        <time_frame>12 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O2">
            <title>100 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O3">
            <title>150 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS) Pain at 12 Hours</title>
          <description>Visual analog pain scale measures pain on a 100 millimeter (mm) scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst pain imaginable&quot; (100mm). Pain measured at rest and with movement.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="0" upper_limit="35"/>
                    <measurement group_id="O2" value="15" lower_limit="0" upper_limit="36"/>
                    <measurement group_id="O3" value="10" lower_limit="3" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Movement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="10" upper_limit="60"/>
                    <measurement group_id="O2" value="35" lower_limit="17" upper_limit="63"/>
                    <measurement group_id="O3" value="30" lower_limit="11" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS) Pain at 18 Hours</title>
        <description>Visual analog pain scale measures pain on a 100 millimeter (mm) scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst pain imaginable&quot; (100mm). Pain measured at rest and with movement.</description>
        <time_frame>18 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O2">
            <title>100 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O3">
            <title>150 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS) Pain at 18 Hours</title>
          <description>Visual analog pain scale measures pain on a 100 millimeter (mm) scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst pain imaginable&quot; (100mm). Pain measured at rest and with movement.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="0" upper_limit="35"/>
                    <measurement group_id="O2" value="11" lower_limit="0" upper_limit="28"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Movement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="10" upper_limit="50"/>
                    <measurement group_id="O2" value="30" lower_limit="0" upper_limit="40"/>
                    <measurement group_id="O3" value="26" lower_limit="0" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS) Pain at 24 Hours</title>
        <description>Visual analog pain scale measures pain on a 100 millimeter (mm) scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst pain imaginable&quot; (100mm). Pain measured at rest and with movement.</description>
        <time_frame>24 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O2">
            <title>100 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O3">
            <title>150 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS) Pain at 24 Hours</title>
          <description>Visual analog pain scale measures pain on a 100 millimeter (mm) scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst pain imaginable&quot; (100mm). Pain measured at rest and with movement.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="9" upper_limit="43"/>
                    <measurement group_id="O2" value="21" lower_limit="6" upper_limit="50"/>
                    <measurement group_id="O3" value="18" lower_limit="0" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Movement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="22" upper_limit="65"/>
                    <measurement group_id="O2" value="41" lower_limit="21" upper_limit="68"/>
                    <measurement group_id="O3" value="41" lower_limit="21" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale- Nausea/Vomiting at 6 Hours</title>
        <description>Visual analog nausea/vomiting scale measures nausea and vomiting on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Nausea/Vomiting Imaginable&quot; (100mm).</description>
        <time_frame>6 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O2">
            <title>100 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O3">
            <title>150 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale- Nausea/Vomiting at 6 Hours</title>
          <description>Visual analog nausea/vomiting scale measures nausea and vomiting on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Nausea/Vomiting Imaginable&quot; (100mm).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="15"/>
                    <measurement group_id="O2" value="7" lower_limit="0" upper_limit="40"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale- Nausea/Vomiting at 12 Hours</title>
        <description>Visual analog nausea/vomiting scale measures nausea and vomiting on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Nausea/Vomiting Imaginable&quot; (100mm).</description>
        <time_frame>12 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O2">
            <title>100 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O3">
            <title>150 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale- Nausea/Vomiting at 12 Hours</title>
          <description>Visual analog nausea/vomiting scale measures nausea and vomiting on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Nausea/Vomiting Imaginable&quot; (100mm).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale- Nausea/Vomiting at 18 Hours</title>
        <description>Visual analog nausea/vomiting scale measures nausea and vomiting on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Nausea/Vomiting Imaginable&quot; (100mm).</description>
        <time_frame>18 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O2">
            <title>100 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O3">
            <title>150 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale- Nausea/Vomiting at 18 Hours</title>
          <description>Visual analog nausea/vomiting scale measures nausea and vomiting on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Nausea/Vomiting Imaginable&quot; (100mm).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale- Nausea/Vomiting at 24 Hours</title>
        <description>Visual analog nausea/vomiting scale measures nausea and vomiting on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Nausea/Vomiting Imaginable&quot; (100mm).</description>
        <time_frame>24 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O2">
            <title>100 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O3">
            <title>150 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale- Nausea/Vomiting at 24 Hours</title>
          <description>Visual analog nausea/vomiting scale measures nausea and vomiting on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Nausea/Vomiting Imaginable&quot; (100mm).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale Pruritus (Itching) at 6 Hours</title>
        <description>Visual analog pruritus scale measures itching on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Itching Imaginable&quot; (100mm).</description>
        <time_frame>6 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O2">
            <title>100 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O3">
            <title>150 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale Pruritus (Itching) at 6 Hours</title>
          <description>Visual analog pruritus scale measures itching on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Itching Imaginable&quot; (100mm).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="10" upper_limit="45"/>
                    <measurement group_id="O2" value="37" lower_limit="3" upper_limit="73"/>
                    <measurement group_id="O3" value="39" lower_limit="19" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale Pruritus (Itching) at 12 Hours</title>
        <description>Visual analog pruritus scale measures itching on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Itching Imaginable&quot; (100mm).</description>
        <time_frame>12 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O2">
            <title>100 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O3">
            <title>150 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale Pruritus (Itching) at 12 Hours</title>
          <description>Visual analog pruritus scale measures itching on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Itching Imaginable&quot; (100mm).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="0" upper_limit="20"/>
                    <measurement group_id="O2" value="23" lower_limit="0" upper_limit="64"/>
                    <measurement group_id="O3" value="25" lower_limit="0" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale Pruritus (Itching) at 18 Hours</title>
        <description>Visual analog pruritus scale measures itching on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Itching Imaginable&quot; (100mm).</description>
        <time_frame>18 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O2">
            <title>100 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O3">
            <title>150 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale Pruritus (Itching) at 18 Hours</title>
          <description>Visual analog pruritus scale measures itching on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Itching Imaginable&quot; (100mm).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="0" upper_limit="20"/>
                    <measurement group_id="O2" value="13" lower_limit="0" upper_limit="47"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale Pruritus (Itching) at 24 Hours</title>
        <description>Visual analog pruritus scale measures itching on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Itching Imaginable&quot; (100mm).</description>
        <time_frame>24 hours post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O2">
            <title>100 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O3">
            <title>150 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale Pruritus (Itching) at 24 Hours</title>
          <description>Visual analog pruritus scale measures itching on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;None&quot; (0mm) and the other labeled &quot;Worst Itching Imaginable&quot; (100mm).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="0" upper_limit="16"/>
                    <measurement group_id="O2" value="12" lower_limit="0" upper_limit="39"/>
                    <measurement group_id="O3" value="6" lower_limit="0" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Patient Satisfaction With Analgesia at 24 Hours</title>
        <description>Visual analog patient satisfaction scale measures satisfaction with analgesia on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;Completely Dissatisfied&quot; (0mm) and the other labeled &quot;Completely Satisfied&quot; (100mm).</description>
        <time_frame>24 hours postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O2">
            <title>100 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
          <group group_id="O3">
            <title>150 Micrograms Spinal Morphine</title>
            <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Patient Satisfaction With Analgesia at 24 Hours</title>
          <description>Visual analog patient satisfaction scale measures satisfaction with analgesia on a 100mm scale. Participants make a mark on the scale with one end labeled &quot;Completely Dissatisfied&quot; (0mm) and the other labeled &quot;Completely Satisfied&quot; (100mm).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="65" upper_limit="100"/>
                    <measurement group_id="O2" value="83" lower_limit="67" upper_limit="100"/>
                    <measurement group_id="O3" value="84" lower_limit="70" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>50 Micrograms Spinal Morphine</title>
          <description>Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed and analyzed with 47 in this group</description>
        </group>
        <group group_id="E2">
          <title>100 Micrograms Spinal Morphine</title>
          <description>Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed and analyzed with 54 in this group</description>
        </group>
        <group group_id="E3">
          <title>150 Micrograms Spinal Morphine</title>
          <description>Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section&#xD;
Morphine: Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section&#xD;
After interim analysis, the genetics part of the analysis was dropped and the study completed and analyzed with 43 in this group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard Smiley, MD</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-342-2742</phone>
      <email>rms7@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

